{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:21:00Z","timestamp":1792102860863,"version":"4.4.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T00:00:00Z","timestamp":1383955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>\n                      To test a new drug delivery platform with dorzolamide \u03b3-cyclodextrin (\u03b3CD) nanoparticle eye drops for intraocular pressure (IOP) control and safety and compare with Trusopt.\n                      <jats:sup>\u00ae<\/jats:sup>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Self-aggregating \u03b3CD nanoparticle eye drops containing 3% dorzolamide were given once a day (QD) and compared with Trusopt given three times a day (TID) in a prospective randomized single masked crossover trial over 24\u2009h. Seventeen subjects with IOP over 18\u2009mmHg were recruited. IOP was measured with an Icare Tonometer Pro.\n                      <jats:sup>\u00ae<\/jats:sup>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      There was no statistically significant difference in the IOP lowering effect of dorzolamide nanoparticle eye drops QD and Trusopt TID. At peak (4\u2009h), the IOP reduction from baseline was 3.8\u00b12.6\u2009mmHg (18%,\n                      <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>\n                      0.05) in the nanoparticle eye drop group and 3.1\u00b13.7\u2009mmHg in the Trusopt group (14%,\n                      <jats:italic toggle=\"yes\">P&lt;<\/jats:italic>\n                      0.05,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.97 between groups). At trough (24\u2009h), the IOP reduction was 1.4\u00b12.8\u2009mmHg (6%,\n                      <jats:italic toggle=\"yes\">P&gt;<\/jats:italic>\n                      0.05) in nanoparticle eye drop group and 1.5\u00b12.0\u2009mmHg (7%,\n                      <jats:italic toggle=\"yes\">P&gt;<\/jats:italic>\n                      0.05) in the Trusopt group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.23 between groups). Burning sensation measured on the visual analogue scale (1\u2013100) was less from the nanoparticle eye drops (12\u00b115) than from the Trusopt (37\u00b130), (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.0038). Visual acuity and conjunctival hyperemia did not differ between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Dorzolamide cyclodextrin nanoparticle eye drops QD lower IOP and the effect seems comparable to Trusopt given TID. The nanoparticle eye drops are well tolerated and seem to have a better safety profile than Trusopt.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2013.0060","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T09:18:24Z","timestamp":1383988704000},"page":"35-41","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":30,"title":["\u03b3-Cyclodextrin Nanoparticle Eye Drops with Dorzolamide: Effect on Intraocular Pressure in Man"],"prefix":"10.1177","volume":"30","author":[{"given":"Birna S.","family":"Gudmundsdottir","sequence":"first","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyrleif","family":"Petursdottir","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun M.","family":"Asgrimsdottir","sequence":"additional","affiliation":[{"name":"Oculis ehf","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Gottfredsdottir","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveinn H.","family":"Hardarson","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]},{"name":"University of Iceland","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauti","family":"J\u00f3hannesson","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]},{"name":"Ume\u00e5 University","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey V.","family":"Kurkov","sequence":"additional","affiliation":[{"name":"University of Iceland","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phatsawee","family":"Jansook","sequence":"additional","affiliation":[{"name":"Oculis ehf","place":["Iceland"]},{"name":"University of Iceland","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsteinn","family":"Loftsson","sequence":"additional","affiliation":[{"name":"Oculis ehf","place":["Iceland"]},{"name":"University of Iceland","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Stef\u00e1nsson","sequence":"additional","affiliation":[{"name":"Landspitali University Hospital","place":["Iceland"]},{"name":"Oculis ehf","place":["Iceland"]},{"name":"University of Iceland","place":["Iceland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,11,9]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2012.06.055"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2010.07.005"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02299.x"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80109-0"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/yakushi.121.799"},{"key":"e_1_3_3_7_2","volume-title":"European Pharmacopoeia","author":"Council of Europe","year":"2006","unstructured":"Council of Europe. European Pharmacopoeia. 5th ed. France: S, 2006.","edition":"5"},{"key":"e_1_3_3_8_2","first-page":"501","volume-title":"Martin's Physical Pharmacy and Pharmaceutical Sciences","author":"Sinko P.J","year":"2006","unstructured":"Sinko P.J, Martin's Physical Pharmacy and Pharmaceutical Sciences, fifth ed. Philadelphia: Lippincott Williams & Wilkins; 2006; pp. 501\u2013503."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.10.004"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2011.02.008"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6702295"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(83)90126-4"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8178"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cocis.2005.11.001"},{"key":"e_1_3_3_15_2","first-page":"363","article-title":"Drug permeation through biomembranes: cyclodextrins and the unstirred water layer","volume":"67","author":"Loftsson T.","year":"2012","unstructured":"Loftsson T. Drug permeation through biomembranes: cyclodextrins and the unstirred water layer. Pharmazie., 67:363\u2013370, 2012.","journal-title":"Pharmazie."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2011.01279.x"},{"key":"e_1_3_3_17_2","first-page":"1463","volume-title":"The Glaucomas.","author":"Lippa EA.","year":"1996","unstructured":"Lippa EA. Carbonic anhydrase inhibitors. In: Ritch R., , Shields M.B., , Krupin T., eds. The Glaucomas. St Louis: Mosby; 1996; p. 1463\u20131481."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080160073033"},{"key":"e_1_3_3_19_2","first-page":"308","article-title":"MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors","volume":"98","author":"Lippa EA Schuman J.S.","year":"1991","unstructured":"Lippa EA Schuman J.S., , Higginbotham E.J., et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophtalmology., 98:308\u2013312, 1991.","journal-title":"Ophtalmology."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1993.01090100051026"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)72009-4"},{"key":"e_1_3_3_22_2","first-page":"3552","article-title":"Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension","volume":"41","author":"Gu\u00f0mundsd\u00f3ttir E.","year":"2000","unstructured":"Gu\u00f0mundsd\u00f3ttir E., , Stef\u00e1nsson E., , Bjarnad\u00f3ttir G., et al. Methazolamide 1% in cyclodextrin solution lowers IOP in human ocular hypertension. Invest. Ophthalmol. Vis. Sci., 41:3552\u20133554, 2000.","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.1996.tb01549.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/03639041003801885"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02569066"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.01112.x"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0039-6257(93)90053-A"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210901900516"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.024"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2013.0060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2013.0060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2013.0060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:38:47Z","timestamp":1777646327000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2013.0060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,9]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2,1]]}},"alternative-id":["10.1089\/jop.2013.0060"],"URL":"https:\/\/doi.org\/10.1089\/jop.2013.0060","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,9]]}}}